IFN-γ–related mRNA profile predicts clinical response to PD-1 blockadeMark Ayers, Terrill K. McClanahan, Jared Lunceford et al.|Journal of Clinical Investigation|2017Cited by 3.9k
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapyRăzvan Cristescu, David R. Kaufman, Robin Mogg et al.|Science|2018Cited by 2.3k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E.W. Cohen, Signe Friesland, Kelvin Chan et al.|The Lancet|2018Cited by 1.7k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion CohortLaura Q.M. Chow, Tanguy Y. Seiwert, Robert I. Haddad et al.|Journal of Clinical Oncology|2016Cited by 859
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II StudyJoshua Bauml, Robert I. Haddad, Tanguy Y. Seiwert et al.|Journal of Clinical Oncology|2017Cited by 653